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Abstract
Background: Recent genome-wide association (GWA) analyses have identified common single nucleotide
polymorphisms (SNPs) that are associated with obesity. However, the reported genetic variation in obesity explains
only a minor fraction of the total genetic variation expected to be present in the population. Thus many genetic
variants controlling obesity remain to be identified. The aim of this study was to use GWA followed by multiple
stepwise validations to identify additional genes associated with obesity.
Methods: We performed a GWA analysis in 164 morbidly obese subjects (BMI:body mass index > 40 kg/m
2) and
163 Swedish subjects (> 45 years) who had always been lean. The 700 SNPs displaying the strongest association
with obesity in the GWA were analyzed in a second cohort comprising 460 morbidly obese subjects and 247
consistently lean Swedish adults. 23 SNPs remained significantly associated with obesity (nominal P< 0.05) and
were in a step-wise manner followed up in five additional cohorts from Sweden, France, and Germany together
comprising 4214 obese and 5417 lean or population-based control individuals. Three samples, n = 4133, were used
to investigate the population-based associations with BMI. Gene expression in abdominal subcutaneous adipose
tissue in relation to obesity was investigated for14 adults.
Results: Potassium channel, calcium activated, large conductance, subfamily M, alpha member (KCNMA1)
rs2116830*G and BDNF rs988712*G were associated with obesity in five of six investigated case-control cohorts. In
meta-analysis of 4838 obese and 5827 control subjects we obtained genome-wide significant allelic association
with obesity for KCNMA1 rs2116830*G with P = 2.82 × 10
-10 and an odds ratio (OR) based on cases vs controls of
1.26 [95% C.I. 1.12-1.41] and for BDNF rs988712*G with P = 5.2 × 10
-17and an OR of 1.36 [95% C.I. 1.20-1.55].
KCNMA1 rs2116830*G was not associated with BMI in the population-based samples. Adipose tissue (P = 0.0001)
and fat cell (P = 0.04) expression of KCNMA1 was increased in obesity.
Conclusions: We have identified KCNMA1 as a new susceptibility locus for obesity, and confirmed the association
of the BDNF locus at the genome-wide significant level.
Background
Several susceptibility loci for high BMI and obesity have
recently been identified by genome-wide association
(GWA) analyses of both large population-based samples
and samples including extreme obese phenotypes [1-11].
Analysis of the latter group is based on the assumption
that subjects with an extreme phenotype, such as mor-
bid obesity, may be enriched for variants that influence
the risk of developing obesity [7]. It is possible that
extreme phenotypes of common disorders are due to
rare. but highly penetrant, alleles that are difficult to
identify by GWA analysis based on common single
nucleotide polymorphisms (SNPs). However, based on
GWA analysis of extreme obesity, Cotsapas et al found
no evidence for rare highly penetrant alleles and con-
cluded that most cases of severe obesity are extremes of
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any medium, provided the original work is properly cited.the phenotypic spectrum rather than a distinct condition
[6]. However, this does not exclude the existence of rare
variants underlying specific cases of morbid obesity
[12-14].
Susceptibility genes for human obesity are believed to
act primarily on the central regulation of food intake.
Three reported susceptibility loci for obesity harbour
genes that are known to be involved in catabolic
hypothalamic pathways (MC4R, PCSK1, and BDNF)a n d
many others contain genes that are highly expressed in
the central nervous system [11,15,16]. However, studies
in mice mutated for Fto, the homolog of the human
obesity susceptibility gene FTO, have demonstrated per-
ipheral metabolic effects of this gene [17,18]. Overall,
the mechanisms of action of most obesity genes are not
well understood and adipose tissue, as well as skeletal
muscle, which are sites for storage, release, and metabo-
lism of fatty acids, may be involved.
Overall, the reported genetic variation in obesity
explains only a minor fraction of the total genetic varia-
tion expected to be present in the population. In the
most recent GWA meta-analysis, 32 obesity loci
explained together only about 2-4% of the genetic varia-
tion in BMI [11]. Thus, much of the genetic variation
controlling obesity remains to be discovered [11,15,19].
In this study we report the identification of a novel sus-
ceptibility gene for obesity by GWA analysis of morbidly
obese cases and controls that have a lifelong history of
leanness. The association for this gene was confirmed in
five independent case versus control cohorts, as well as
in population based samples. Finally, we quantified the
expression of the novel gene contributing to obesity in
human adipose tissue samples.
Methods
Cohorts
The cohorts for genetic studies of obesity and BMI are
described in Tables 1 and 2. The GWA analysis was
performed for the Swedish cohort 1 comprising subjects
(age 16-73 years) with morbid obesity (BMI ≥40.0 kg/
m
2), and lean subjects > 45 years old who never had
been overweight (BMI always < 25.0 kg/m
2). All subjects
in Cohort 1 were at least third generation Scandinavian
and lived in Sweden. Swedish cohort 2 was used for
initial replication of the GWA results and had identical
inclusion criteria. Swedish cohort 3 comprised obese
adults with BMI ≥30.0 kg/m
2 and lean subjects who
were > 25 years old and had BMI < 25.0 kg/m
2,a l lh a v -
ing European ancestry and from the greater Stockholm
area. Cohorts 1, 2 and 3 were selected according to the
above BMI inclusion criteria amongst subjects recruited
by local advertisements or amongst participants in
population-based surveys or case-control studies of
myocardial infarction (282 had myocardial infarction, of
which 89 were obese). These cohorts included subjects
diagnosed with type 2 diabetes (n = 301), hypertension
(n = 810) or dyslipidemia (n = 385). Patients with
chronic inflammatory diseases other than cardiovascular
disease, type 1 diabetes mellitus, renal insufficiency
(serum creatinine > 200 μmol/L), drug addiction or psy-
chiatric disease were excluded.
Cohort 4 comprised French obese and population-
based control children. Obese children living in the
Paris area were consecutively recruited starting in 2001.
Obesity was assessed by BMI Z-scores [standard devia-
tion (SD) over mean BMI at a given age and sex for a
French reference population]. Obese children had a BMI
Z-score ≥3 SD above the means specific for age and sex
in normal French children as described previously
Table 1 Cohorts for genetic studies
obese cases lean and population-based controls
Cohort SNP§ Nationality female/male BMI* (kg/m
2) age* (years) female/male BMI* (kg/m
2) age* (years)
Discovery 1 406,177 Swedish 131/33
§ 44.7 ± 4.7 43.8 ± 12.6 137/26 22.2 ± 1.8 51.6 ± 6.1
Replication 2 700 Swedish 370/90
§§ 44.6 ± 4.6 42.2 ± 13.2 206/41 22.6 ± 1.7 51.6 ± 5.3
Replication 3 21 Swedish 1025/789 37.1 ± 5.4 46.6 ± 11.4 819/885 22.8 ± 1.7 48.7 ± 10.8
Replication 4** 21 French 641/344 33.7 ± 8.2 14.1 ± 5.0 289/243
# 18.7 ± 3.3 11.8 ± 1.6
Replication 5 2 French 682/246 48.5 ± 7.6 43.0 ± 12.1 1630/1108
# 23.8 ± 3.5 49.7 ± 6.3
Replication 6** 2 German 278/209 33.4 ± 6.8 14.4 ± 3.7 271/171 18.3 ± 1.1 16.1 ± 5.8
Total 3127/1711 3353/2474
* Values are mean ± SD; ** Cohorts comprising children in which case BMI Z-scores were used to define obesity status as defined in Methods.
§ Number of SNPs genotyped in each cohort. The 700 most significantly obesity associated SNPs in the GWA were analyzed in cohort 2 (threshold P = 0.003).
Subsequently, nominal association with obesity was used as threshold to determine whether a SNP would be followed up by genotyping additional cohorts. #
population-based controls
Table 2 Population-based cohorts for analysis of BMI
nationality cohort Female/male BMI* (kg/m
2) age* (years)
French 5§ 1630/1108 23.8 ± 3.5 49.7 ± 6.3
Swedes 7 545/0 25.3 ± 3.9 43.9 ± 4.3
Danes 8 0/850 26.1 ± 3.6 43.0 ± 6.0
Values are mean ± SD; **Number of SNPs that were genotyped in each
cohort.
§ This cohort is identical to the population-based controls in table 1
Jiao et al. BMC Medical Genomics 2011, 4:51
http://www.biomedcentral.com/1755-8794/4/51
Page 2 of 10[20,21]. The control children participated in a popula-
tion-based physical activity study [22]. Phenotypes were
collected before the physical activity intervention.
Cohort 5 comprised adult French obese cases and
population-based control subjects. Obese adults living in
the Paris area were consecutively recruited and had
morbid obesity (BMI ≥40.0 kg/m
2). The adults in the
control group were participants of SU.VI.MAX, which is
a study to test antioxidant supplementation [23]. A sub-
set of 2738 subjects living in Paris was used as controls
in the present study. Phenotypes were collected at study
entry. Women are more likely to respond to advertise-
ments for participation in obesity research, which
explains the female-biased gender ratio in cohorts 1 and
2, and among the obese in cohorts 4 and 5.
Cohort 6 encompassed German extremely obese chil-
dren and adolescents (mean BMI Z score 4.6 ± 2.3) and
adult lean controls (mean BMI Z score: -1.4 ± 0.4) (for
details see [3]). The BMI of the obese patients was
above the 90th BMI percentile for German children and
adolescents (see http://www.mybmi.de). 91% of the
obese patients had a BMI above the 97th percentile.
The lean adult controls were all students at Marburg
University.
In order to assess the association between SNPs and
BMI, two additional population-based adult cohorts
were genotyped, besides the controls in cohort 4 (Table
2). Cohort 7 encompassed 545 adult women who were
recruited in Stockholm (see [24] for details). Cohort 8
encompassed 850 Danish men randomly selected from
the mandatory draft board examinations 1943-1977 and
investigated 1998-2000 (see [25] for details). Thus, 2175
women (mean age 47 years) and 1958 men (mean age
50 years) were genotyped in the population-based sur-
vey. The population based cohorts 7 and 8 contained
very few subjects with morbid obesity and were there-
fore not included in the meta-analysis of obesity in
cases versus controls. Case-control and population-
based samples have apparently no familial links although
relatedness has not been firmly tested. However, the
absence of apparent relatedness in cohort 1 was sup-
ported by the strong overlap between expected and
observed p-values in the Q-Q plot (additional file 1, Fig-
ure S1).
Subjects included in analysis of human abdominal
subcutaneous adipose tissue were from cohort 3 (see
above). In these studies obesity was defined as BMI > 30
kg/m
2 and leanness as BMI < 25 kg/m
2.A l ls u b j e c t s
were healthy according to self-report. Expression of spe-
cific genes in relation to obesity was investigated in
s e v e nl e a n( 5w o m e na n d2m e nw i t hB M I2 3 . 3±1 . 7
kg/m
2 and age 33.0 ± 9.8 years) and seven obese sub-
jects (6 women and 1 man with BMI 34.4 ± 5.9 kg/m
2
and age 48.6 ± 12.2).
Ethical approval
The studies had been approved by the local Ethics Com-
mittee. Each subject gave informed written consent to
the study. For subjects less than 18 years of age, authori-
zation was obtained from the parents.
Genotyping
The strategy used to find obesity genes is shown in Fig-
ure 1. The GWA study was performed for Cohort 1 on
the Affymetrix 500K Gene chip arrays (Affymetrix,
Santa Clara, CA) assaying 489,922 autosomal SNPs.
Genotypes were first called using the DM model imple-
mented in GeneChip
® Genotyping Analysis Software
(GTYPE) Version 4.0 (Affymetrix) with default para-
meters. All arrays had call rates ≥93% and were then
assessed using the BRLMM model. The average call rate
based on the BRLMM model was 98.6%. Quality control
of SNPs was performed as described in the additional
file 1. After quality control, a total of 406,177 autosomal
SNPs were analyzed for association with obesity. The
additional file 1, Table S1, shows the result of the qual-
ity control and chromosomal distribution of analyzed
SNPs.
The statistical power of cohort 1 was limited and we
did not expect to obtain genome-wide significance in
this discovery cohort. We therefore followed up a large
number of nominally significant obesity-associated SNPs
in a step-wise manner by genotyping additional cohorts,
starting with cohort Swedish 2. We selected the 755
SNPs with the lowest p-values for allelic association
with obesity in the GWA study, with the exception that
for SNPs in close linkage disequilibrium according to
our GWA data (SNPs which were carried on identical
haplotypes according to HaploView with default set-
tings) only one was included for further analysis, for
genotyping using Illumina Golden Gate assays (Illumina
Inc.). Thus, the 755 SNPs represented unlinked loci
across the human genome. 755 SNPs were chosen since
this number would maximize the efficient use of the
genotyping platform. As a consequence of the applied
s e l e c t i o nm e t h o dt h et h r e s h o l df o rf o l l o w i n gu pa n d
genotyping a SNP in cohort 2 was a p-value of 0.003 (p-
value range 0.003 to 1.17 × 10
-6) for association with
obesity in the GWA. Of the SNPs selected for follow-
up, 700 were successfully genotyped.
Subsequent genotyping for cohorts 3, 4, and 5 (cases),
and 7 were performed with matrix-assisted laser deso-
rption/ionization time-of-flight mass spectrometry
(SEQUENOM). The SU.VI.MAX control cohort 5 and
the cohort 8 were genotyped by TaqMan (Applied Bio-
systems, Foster City, CA and K Biosciences, Herts, UK,
respectively). Thus all above cohorts were de novo geno-
typed in this project. By contrast for cohort 7 we per-
formed in silico replication using available Affymetrix
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Page 3 of 106.0 GWA genotypes [3]. All of cohort 1 and cohort 2
were genotyped twice for rs2116830 with different
methods and all genotypes were concordant between
platforms.
Adipose tissue samples
Abdominal subcutaneous biopsies were obtained during
elective surgery for non-malignant disorders after an
overnight fast. Fat cells were isolated as described [26].
Adipose tissue pieces (300 mg) or 200 μli s o l a t e d
adipocytes were immediately frozen in liquid nitrogen
and kept at -70°C for subsequent RNA isolation.
cDNA synthesis and quantitative real-time PCR
Total RNA was extracted from adipose tissue samples
and transcribed to cDNA as described previously [27].
KCNMA1 and the reference gene 18S were quantified
using SYBR Green-based quantitative real-time PCR
(qRT-PCR). Primers were for KCNMA1: 5’- CAGAAGT
TGGCTTGGTTTGAG -3’ and 5’- ATGGAGAGCA
Discovery, 406,177 SNPs
Extension study
Extension study
Extension study
Adults with morbid obesity 
or lifelong leanness (1)*
700 most strongly obesity associated SNPs**
21 SNPs nominally associated with obesity
Adults with morbid obesity 
or lifelong leanness (2)
2 SNPs nominally associated with obesity
KCNMA1 (rs2116830), BDNF (rs988712)
Obese and lean adults (3)
Obese and population-based 
control children (4)
Morbid obese and population-
based  control adults (5)
Obese and lean chilldren (6)
Expression 
studies
(KCNMA1)
Meta-analysis
All case-
control
cohorts
Association to
body mass 
index
Three population 
based samples (5,7,8)
KCNMA1 (rs2116830) KCNMA1 (rs2116830), 
BDNF (rs988712)
Figure 1 Strategy for Genome wide association analysis. *Phenotypes of studied cohorts with cohort number within parenthesis. **Number
of SNPs taken forward for genotyping and analysis in subsequent cohorts.
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Page 4 of 10GATTCACCAG -3’,a n df o r1 8 S :5 ’- CACATGGCCTC-
CAAGGAGTAAG -3’ and 5’- CCAGCAGTGAGGGT
CTCTCT -3’. 5 ng of cDNA was mixed with gene speci-
fic primers (final concentration 300 nM) and IQ™
SYBR Green supermix (Bio-Rad Laboratories, Hercules,
CA, USA) and amplified with an iCycler IQ (Bio-Rad
Laboratories, Hercules, CA, USA) according to the man-
ufacturer’s instructions. Dissociation curve analyses and
agarose gel electrophoresis were used to validate that a
single amplicon was amplified. All reactions were run in
duplicate. Relative gene expression was calculated using
a direct comparative method (User Bulletin #2, Applied
Biosystems).
Statistical analysis
Hardy-Weinberg equilibrium (HWE) of the genotypic
frequencies among cases and controls were tested sepa-
rately prior to association analyses. P< 0.001 in controls
was used as cut-off for exclusion of failed SNPs from
further analysis. This is a conventional cut-off for exclu-
sion of failed SNPs in GWA studies.
Association between single SNPs and obesity status was
performed in the same manner in the GWA study and in
the extension studies. Initially association was evaluated
by allelic association; allele frequencies were compared
between obese and control populations by the c
2 test
using in-house programs. We chose a test of allelic asso-
ciation since we had no a priori assumption which
genetic model best explains SNP association with obesity.
Distribution of p-values in the GWA study was presented
as Q-Q and Manhattan plots, which were generated
using the R package [28]. We performed meta-analysis of
the association between obesity and individual SNPs
across the six investigated case-control cohorts. The
inverse variance method was used for pooling of cohort
results. The combination of data and the combined value
of the odds ratio (OR) and 95% confidence interval (C.I.)
were calculated using the random effects estimate
method implemented in the R package, and meta-analysis
plots were generated using the R package. For the genetic
loci that displayed genome-wide allelic association with
obesity, model-based tests were carried out to evaluate
association of genotype with obesity using logistic regres-
sion implemented in PLINK [29]. Models were tested for
the effect allele [30].
rs2116830 was evaluated for association with BMI in
population-based cohorts by linear regression as imple-
mented in PLINK. The Wald test was performed to give
asymptotic p-value for significance. Statistical power was
calculated as described [31] based on mean and SD for
BMI of all adult populations-based samples.
Differences in KCNMA1 mRNA between two groups
were evaluated by two-sided unpaired Student’stt e s t .
Values are mean ± SD.
Results
We performed a GWA analysis of morbidly obese cases
and controls that have a lifelong history of leanness.
The distribution of p-values for all SNPs that were ana-
lyzed for association with obesity is shown in the addi-
tional file 1, Figure S1 (Q-Q plot) and S2 (Manhattan
plot). No SNP displayed genome-wide significant asso-
ciation with obesity in the GWA, that is P<1 0
-7.T h e
SNPs showing the strongest association in the GWA
were analyzed in additional case-control cohorts 700
SNPs were successfully genotyped in cohort 2. Of these,
23 were nominally associated with obesity with consis-
tent effect direction as observed for the GWA (addi-
tional file 1, Table S2). 21 of these SNPs (one SNP assay
failed and another SNP had already been investigated as
a candidate gene [32]) were subsequently analyzed in
S w e d i s hc o h o r t3a n dF r e n c hc o h o r t4 .T w oo ft h e2 1
SNPs displayed consistent effect direction and nominal
significant association with obesity in these cohorts,
rs2116830, and rs988712 (additional file 1, Table S2,
Table 3). These two SNPs were subject to further
confirmation.
The G-allele of rs2116830, located in intron 28 of the
gene Potassium channel, calcium activated, large conduc-
tance, subfamily M, alpha member (KCNMA1) on chro-
mosome 10, showed consistent effect direction and
significant allelic association with obesity in the French
cohort 5 comprising morbidly obese adults and popula-
tion-based adult control subjects (P = 0.0017), but not in
the German cohort 6 comprising morbidly obese youth
and adult lean controls (P = 0.35) (Table 3, Figure 2A).
The overall meta-analysis p-value for cases vs controls
showed genome-wide significance (P =2 . 8 2×1 0
-10) with
an odds ratio (OR) of 1.26 [95% C.I. 1.12-1.41], with no
statistical evidence for heterogeneity in impact on obesity
between cohorts (Figure 2A). The impact of the G-allele
of rs2116830 on obesity under different genetic models
was tested in a joint analysis of all case-control cohorts.
The recessive, P =2 . 5×1 0
-9 (OR 1.30 [95% C.I. 1.19-
1.42]), but not the additive or dominant genetic model
reached genome-wide significance (Table 4).
rs988712*G, which is located 113,058 base pairs
downstream of the established obesity locus BDNF on
chromosome 11 [8], showed consistent effect direction
and was significantly associated with obesity in the
French cohort 5 (P = 0.0020), but not in the German
cohort 6 (P = 0.135). The overall meta-analysis p-value
for association with obesity showed genome-wide signif-
icance (P =5 . 2×1 0
-17)w i t ha nO Ro f1 . 3 6[ 9 5 %C . I .
1.20-1.55] (Figure 2B). There was statistical evidence for
heterogeneity in impact on obesity between cohorts for
rs988712 (P = 0.027). Additive, dominant and recessive
genetic models reached genome-wide significance and
the G-allele of rs988712 was associated with obesity in
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Page 5 of 10Table 3 GWA SNPs with confirmed allelic association with obesity in extension studies
Chr. Gene Effect allele* Cohort** Call rate (%) Obese Controls P§§
GG/GT/TT %§ GG/GT/TT %§
10 KCNMA1 rs2116830G 1 98 121/35/4 87 91/59/9 76 5.0 × 10
-04
2 99 314/126/9 84 153/74/13 79 0.019
3 99 1232/499/53 83 1108/522/61 81 0.018
4 98 684/232/25 85 348/161/16 82 0.024
5 97 598/263/26 82 1065/576/81 79 0.0017
6 100 318/125/9 83 295/128/12 84 0.35
Pooled 3267/1180/126 3060/1520/192 2.8 × 10
-10
11 BDNF rs988712G 1 91 104/53/4 81 86/67/10 73 0.0017
2 99 300/140/13 82 139/83/16 76 0.0095
3 99 1126/590/66 80 976/595/112 76 3.9E-05
4 98 609/283/34 81 273/199/50 71 2.2 ×10
-9
5 95 540/290/41 79 942/642/106 75 0.0019
6 99 273/148/25 78 246/151/33 75 0.13
Pooled 2952/1504/183 2662/1737/327 5.2 × 10
-17
* All SNPs are in HWE with P> 0.05. ** Details about cohorts are given in table 1. § Frequency of effect allele among obese cases and controls. §§ Allele
frequencies were compared by Chi
2-test.
A
B
Figure 2 Meta-analysis of association between (A) KCNMA1 rs2116830*G, and (B) BDNF rs988712*G with obesity in six cohorts.F o r
meta-analysis results were pooled using the inverse variance method. Combined OR and C.I. were calculated using the random effects estimate
method implemented in R.
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Page 6 of 10both men and women (Table 4). Only two of seven obe-
sity-associated SNPs in the BDNF region in [8], rs6265
and rs10501087, were genotyped in our GWA cohort.
Neither showed strong LD with rs988712 in our cohort,
r2 0.57-0.59.
For the new obesity susceptibility locus rs2116830
(KCNMA1) we performed quantitative trait analysis of
BMI in three adult population-based samples, n = 4133
in total (Table 1). One of these cohorts (controls in
French cohort 5) was also used in the case-control stu-
dies described above. For BMI we could detect 1.0 kg/
m
2 difference between genotypes with 93% power with
nominal P of 0.001. There was neither significant asso-
ciation with BMI in any population alone, nor in joint
analysis of all three populations (additional file 1, Table
S3). (The same results were obtained when we included
gender, age, and ethnicity in the analysis (results not
shown). When we compared allele frequencies between
obese cases and non-obese controls in the population
based samples we observed consistent effect direction
(additional file 1, Table S3) as in the case-control analy-
sis of obesity in cohorts 1-5 described above (Table 2).
The results were non-significant; however, this was
expected as the total number of obese cases in the
population-based samples was small. 48 subjects had
BMI > 35 kg/m
2 and 267 subjects had BMI > 30 kg/m
2.
We investigated to what extent our GWA replicated
published obesity or BMI loci that had been identified by
GWA analysis. For each of the more than 30 published
loci, we selected one, or sometimes two, SNPs for which
the strongest association with obesity or BMI had been
reported. 13 of these SNPs, which represented eleven
loci, were analyzed for association with obesity in cohort
1. The remaining SNPs were not represented on the Affy-
metrix 500K Gene chip arrays used for the GWA or the
SNP did not pass our quality control. Besides BDNF,o u r
GWA study confirmed allelic association for MC4R with
nominal P< 0.05 (additional file 1, Table S4).
Adipose tissue expression of KCNMA1 is increased in
obesity
To elucidate potential mechanisms of action of
KCNMA1 rs2116830 in obesity we determined mRNA
levels of in human abdominal subcutaneous adipose tis-
sue from obese and lean subjects. KCNMA1 mRNA was
increased about fourfold in adipose tissue (P = 0.0001)
as well as isolated fat cells (P = 0.04) derived from obese
subjects compared to controls (Figure 3).
Discussion
We have identified one new susceptibility locus for obe-
sity near KCNMA1 (rs2116830) and confirmed associa-
tion with BDNF (rs988712) [8], by GWA analysis in a
limited sample of morbidly obese and lean adults This
study was followed up by genotyping of five additional
European case-control cohorts. Both loci reached gen-
ome-wide significant association with obesity in meta-
analysis of investigated cohorts [33].
Our exploratory GWA study was performed in mor-
bidly obese subjects raising the question to what extent
Table 4 Association of SNPs with obesity under different genetic models
SNP Gender Genetic model Obese (n) Control (n) OR (95% C.I.) P value§§
rs2116830 All Additive* 3267/1280/126 3060/1520/192 1.27 (1.13, 1.43) 4.2 ×10
-05
(KCNMA1) Dominant** 4547/126 4580/192 1.51 (1.20, 1.89) 0.0004
Recessive§ 3267/1406 3060/1712 1.30 (1.19, 1.42) 2.5 × 10
-09
Male Additive 1127/475/48 1311/641/80 1.20 (1.00, 1.44) 0.055
Dominant 1602/48 1952/80 1.37 (0.95, 1.97) 0.092
Recessive 1127/523 1311/721 1.19 (1.03, 1.36) 0.016
Female Additive 2138/805/78 1747/879/111 1.32 (1.14, 1.53) 0.00024
Dominant 2943/78 2626/111 1.60 (1.19, 2.14) 0.0019
Recessive 2138/883 1747/990 1.37 (1.23, 1.53) 2.0 ×10
-08
rs988712 All Additive 2952/1504/183 2662/1737/327 1.41 (1.28, 1.55) 1.1 ×10
-12
(BDNF) Dominant 4456/183 4399/327 1.81 (1.50, 2.18) 3.7 × 10
-10
Recessive 2952/1687 2662/2064 1.36 (1.25, 1.47) 6.2 × 10
-13
Male Additive 1041/519/82 1106/753/140 1.27 (1.10, 1.46) 0.0011
Dominant 1560/82 1859/140 1.43 (1.08, 1.90) 0.012
Recessive 1041/601 1106/893 1.40 (1.22, 1.60) 8.7 × 10
-07
Female Additive 1909/985/101 1554/983/187 1.51 (1.33, 1.71) 1.47 × 10
-10
Dominant 2894/101 2537/187 2.11 (1.65, 2.71) 3.4 × 10
-09
Recessive 1909/1086 1554/1170 1.32 (1.19, 1.47) 2.4 × 10
-07
* Numbers of subject with genotype GG, GT or TT, ** Numbers of subject with genotype GG or GT versus number of subjects with genotype TT, and § numbers
of subject with genotype GG versus GT and T where G is the effect allele;
§§Model based analysis was carried out by logistic regression, se Statistical analysis.
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Page 7 of 10the results are applicable to other groups of obese
patients? Cotsapas et al proposed that severe obesity in
most cases is a condition at the extreme of the phenoty-
pic spectrum rather than a distinct condition, which
suggests that the same genes are involved in all obese
patient groups of the same ethnic origin [6]. However,
the susceptibility loci for morbid obesity identified by
Meyre et al and Scherag et al seemed to have limited or
no impact on BMI in the general population [7,10]. This
may also be true for the novel obesity gene KCNMA1
identified in this study. KCNMA1 rs2116830 was not
associated to BMI in three population based samples. It
is tempting to speculate that KCNMA1 is of minor
importance for the development of a moderate increase
in fat mass, but contribute to excessive accumulation of
adipose tissue in obesity. However, the results from the
population-based cohorts should be interpreted with
caution as the gender-ratio differed widely between sam-
ples. The differences in gender-ratios between the differ-
ent case-control cohorts were smaller and are thus less
likely to confound the results.
Many longitudinal studies show a strong continuity
from mild obesity in childhood to more severe obesity
in adulthood [34]. In addition, most obesity-susceptibil-
ity loci identified by GWA studies in adults are already
associated with anthropometric traits in children/adoles-
cents [35]. Together, this supports a shared genetic
background for early onset and morbid obesity. There
are only few large cohorts available for studies of dis-
tinct forms of obesity. In order to obtain genome-wide
significance we had to include cohorts with different
forms of obesity in the case control analyses [adults
with morbid obesity (BMI > 40 kg/m
2), adult obesity
(BMI 30-40 kg/m
2), and childhood obesity]. The two
susceptibility loci for obesity reported here, KCNMA1
and BDNF displayed nominal allelic association with
obesity in each investigated adult case-control cohort.
However, the associations of KCNMA1 and BDNF with
childhood obesity are less evident and need to be com-
firmed in additional cohorts; with both genes being
associated with obesity in French but not in German
children. Joint analysis of our GWA data on morbid
obese and lean adults, and the GWA data from Hinney’s
et al on obese children and adult lean controls may help
to clarify to what extent morbid and childhood obesity
have a similar genetic background [3].
Among obesity and BMI associated loci reported in
other GWA studies, we could only confirm two, BDNF
and MC4R. One weakness in our analysis was that we,
due to a small sample sizes and different ethnicity, did
not perform imputation of all BMI associated loci in
published GWAs. Our analysis was therefore limited to
published obesity-associated SNPs that produced high
quality genotypes in our study, and encompassed only
eleven out of more than 30 reported loci. The inability
to confirm published obesity loci could be due to small
sample size, different ethnicity, differences in sample
selection and definition of phenotype. Obesity genes are
not necessarily universally detected. Several obesity
genes in previous GWAs could not be replicated in
large European populations [36,37]. All published obe-
sity loci detected by GWA confer a modest to small risk
for obesity. This is also true for KCNMA1 and BDNF in
this study. The odds ratio for developing obesity is 1.26
and 1.36, respectively, for these two loci. The heteroge-
neity between cohorts for impact of BDNF rs988712 on
obesity may be due to differences in ethnicity, age, or
severity of obesity, as well as low power.
In order to further evaluate mechanisms by which
KCNMA1 could contribute to the pathogenesis of obe-
sity we performed gene expression studies in adipose
tissue and observed increased KCNMA1 mRNA expres-
sion in obesity. KCNMA1 encodes one subunit of the
large-conductance voltage- and Ca(2+)-activated K+
channel (BK channel), which is implicated in human
epilepsy, blood pressure regulation, and the risk of myo-
cardial infarction [38,39]. In addition, at cellular levels
stimulation of KCNMA1 channels enhances proliferation
of human pre-adipocytes in vitro [40]. The latter is intri-
guing since it has recently been shown that there is a
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Figure 3 KCNMA1 expression in adipose tissue in relation to obesity. RNA expression in (A) intact adipose tissue and (B) isolated fat cells of
lean (n = 5 women, 2 men) and obese (n = 6 women and n = 1 man) subjects. Relative KCNMA1 expression = 2
(Ct KCNMA1 calibrator- Ct KCNMA1 sample)/
2
(Ct 18S calibrator- Ct 18S sample). Two group comparisons were performed with Student’s t-test. Values are mean ± SD. *** P< 0.0001; * P< 0.05
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Page 8 of 10high rate of adipocyte turnover in vivo; with about 10%
of fat cells being renewed annually [41]. Furthermore,
adipocyte number is a major determinant for the fat
mass in adults [41]. Thus, KCNMA1 could hypotheti-
cally contribute to obesity by increasing number of fat
cells. We did not have access to tissue samples to study
KCNMA1 expression in other organs, including the
organ strongest implicated in regulation of food intake
and obesity, the brain. We therefore cannot exclude a
change of KCNMA1 expression y in other organs in
association with obesity.
Besides small sample size there are other weaknesses
in our GWA., e.g. we did not calculate power and
ancestry principal components, nor did we formally test
for relatedness between subjects.
Conclusions
In conclusion, we identified KCNMA1 as a novel sus-
ceptibility locus for obesity, which may promote obesity
at least in part by acting in adipose tissue. Furthermore,
we confirmed the previously described obesity locus
BDNF. Further studies of KCNMA1 may highlight new
targets for treating obesity.
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